"Immunologic Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
| Descriptor ID |
D007155
|
| MeSH Number(s) |
D27.505.696.477
|
| Concept/Terms |
Immunologic Factors- Immunologic Factors
- Immune Factors
- Factors, Immune
- Immunological Factors
- Factors, Immunological
- Factors, Immunologic
|
Below are MeSH descriptors whose meaning is more general than "Immunologic Factors".
Below are MeSH descriptors whose meaning is more specific than "Immunologic Factors".
This graph shows the total number of publications written about "Immunologic Factors" by people in this website by year, and whether "Immunologic Factors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 4 | 1 | 5 |
| 2006 | 3 | 2 | 5 |
| 2007 | 0 | 1 | 1 |
| 2008 | 3 | 1 | 4 |
| 2009 | 3 | 2 | 5 |
| 2010 | 4 | 0 | 4 |
| 2011 | 2 | 1 | 3 |
| 2012 | 4 | 2 | 6 |
| 2013 | 1 | 2 | 3 |
| 2014 | 2 | 2 | 4 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 1 | 3 |
| 2017 | 2 | 2 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 2 | 3 |
| 2021 | 3 | 3 | 6 |
| 2022 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunologic Factors" by people in Profiles.
-
A Retrospective Review of Tofacitinib in the Treatment of Refractory Dermatomyositis. J Drugs Dermatol. 2022 Oct 01; 21(10):1133-1134.
-
Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy. J Immunother Cancer. 2022 09; 10(9).
-
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. J Hematol Oncol. 2022 06 11; 15(1):80.
-
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. J Transl Med. 2022 06 07; 20(1):257.
-
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma. Cancer Rep (Hoboken). 2022 Nov; 5(11):e1616.
-
New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy. Cells. 2022 02 17; 11(4).
-
Ultralow-dose rituximab in pemphigus: a single-centre experience. Br J Dermatol. 2022 03; 186(3):581-583.
-
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results. J Allergy Clin Immunol Pract. 2022 07; 10(7):1864-1873.e10.
-
Delayed Visual Improvement in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis. Pediatr Neurol. 2022 01; 126:43-45.
-
Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade. J Immunother. 2021 10 01; 44(8):283-291.